Last reviewed · How we verify
Oxycodone/Naloxone controlled-release
Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential.
Oxycodone/naloxone is a controlled-release opioid analgesic combined with an opioid antagonist designed to provide pain relief while reducing abuse potential. Used for Moderate to severe chronic pain requiring continuous opioid therapy.
At a glance
| Generic name | Oxycodone/Naloxone controlled-release |
|---|---|
| Also known as | TARGINIQ ER |
| Sponsor | Purdue Pharma LP |
| Drug class | Opioid analgesic with abuse-deterrent formulation |
| Target | Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonist) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Oxycodone is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia. Naloxone, an opioid antagonist, is included to discourage abuse by blocking opioid effects if the tablet is crushed or dissolved, though naloxone has minimal systemic effect when taken orally as intended. The combination aims to maintain pain control while reducing misuse liability.
Approved indications
- Moderate to severe chronic pain requiring continuous opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Somnolence
- Vomiting
- Headache
- Pruritus
Key clinical trials
- Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (PHASE2, PHASE3)
- Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment (PHASE4)
- A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain (PHASE2)
- OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) (PHASE2)
- A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain (PHASE3)
- Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms (PHASE3)
- Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain (PHASE4)
- Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxycodone/Naloxone controlled-release CI brief — competitive landscape report
- Oxycodone/Naloxone controlled-release updates RSS · CI watch RSS
- Purdue Pharma LP portfolio CI